Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou et al

被引：7
|
作者：
Bettiol, Alessandra [1 ]
Pregnolato, Francesca [2 ]
Sciascia, Savino [3 ,4 ]
Emmi, Giacomo [5 ]
Prisco, Domenico [5 ]
Meroni, Pier Luigi [2 ]
机构：
[1] Univ Florence, Dept Neurosci Psychol Drug Res & Child Hlth NEURO, Florence, Italy
[2] IRCCS, Expt Lab Immunorheumatol, Ist Auxol Italiano, Cusano Milanino, Italy
[3] Osped Torino Nord Emergenza San G Bosco, Dipartimento Malattie Rare Immunol Ematol & Immun, Ctr Ric Immunopatol & Documentaz Malattie Rare, Struttura Complessa Direz Univ Immunol Clin, Turin, Italy
[4] Univ Torino, Turin, Italy
[5] Univ Florence, Dept Expt & Clin Med, I-50134 Florence, Italy
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷 / 08期
关键词：
antibodies; antiphospholipid; biological therapy; lupus erythematosus; systemic; hydroxychloroquine; cardiovascular diseases;
D O I：
10.1136/annrheumdis-2020-218377
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 10 条
  • [1] Response to: 'Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou et al' by Bettiol et al
    Chatzidionysiou, Katerina
    Samoli, Evangelia
    Sfikakis, Petros P.
    Tektonidou, Maria G.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (08)
  • [2] Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus
    Chatzidionysiou, Katerina
    Samoli, Evangelia
    Sfikakis, Petros P.
    Tektonidou, Maria G.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (02) : 304 - +
  • [3] Belimumab Effects on Skin in Patients with Systemic Lupus Erythematosus: A Pooled Post Hoc Analysis of Five Phase 3, Randomized, Placebo-Controlled Clinical Trials
    Manzi, Susan
    Sanchez-Guerrero, Jorge
    Yokogawa, Naoto
    Wenzel, Joerg
    Ocran-Appiah, Josephine C.
    Khamashta, Munther
    Harris, Julia H. N.
    Rubin, Bernie
    Fox, Norma Lynn
    Levy, Roger A.
    Werth, Victoria
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 1933 - 1935
  • [4] Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials
    Parodis, Ioannis
    Lindblom, Julius
    Levy, Roger A.
    Zen, Margherita
    Cetrez, Nursen
    Gomez, Alvaro
    Oon, Shereen
    Henning, Christine
    Khamashta, Munther
    Quasny, Holly A.
    Chauhan, Deven
    Askanase, Anca
    van Vollenhoven, Ronald
    Nikpour, Mandana
    LANCET RHEUMATOLOGY, 2024, 6 (11): : e751 - e761
  • [5] Long-term treatment with metformin in type 2 diabetes and vitamin D levels: A post-hoc analysis of a randomized placebo-controlled trial
    Out, Mattijs
    Top, Wiebe M. C.
    Lehert, Philippe
    Schalkwijk, Casper A.
    Stehouwer, Coen D. A.
    Kooy, Adriaan
    DIABETES OBESITY & METABOLISM, 2018, 20 (08): : 1951 - 1956
  • [6] Comment to "Donor Simvastatin Treatment in Liver Transplantation: Post-hoc Analysis of a Randomized Placebo-controlled Trial With Long-term Follow-up"
    Pagano, Duilio
    Gruttadauria, Salvatore
    TRANSPLANTATION, 2023, 107 (04) : E124 - E124
  • [7] Lurasidone in the treatment of sleep disturbance associated with bipolar depression: post-hoc analysis of a placebo-controlled trial followed by a long-term extension study
    Tsai, J.
    Thase, M.
    Siu, C.
    Pikalov, A.
    Loebel, A.
    BIPOLAR DISORDERS, 2016, 18 : 121 - 122
  • [8] Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A Post-Hoc Analysis of Three Phase III Clinical Trials of Belimumab
    Parodis, Ioannis
    Gomez, Alvaro
    Chow, Jun Weng
    Borg, Alexander
    Lindblom, Julius
    Gatto, Mariele
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [9] Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial
    Wolinsky, Jerry S.
    Arnold, Douglas L.
    Brochet, Bruno
    Hartung, Hans-Peter
    Montalban, Xavier
    Naismith, Robert T.
    Manfrini, Marianna
    Overell, James
    Koendgen, Harold
    Sauter, Annette
    Bennett, Iain
    Hubeaux, Stanislas
    Kappos, Ludwig
    Hauser, Stephen L.
    LANCET NEUROLOGY, 2020, 19 (12): : 998 - 1009
  • [10] FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trial
    Wong, Vincent Wai-Sun
    Anstee, Quentin M.
    Nitze, Louise M.
    Geerts, Anja
    George, Jacob
    Nolasco, Victor
    Kjaer, Mette S.
    Ladelund, Steen
    Newsome, Philip N.
    Ratziu, Vlad
    ECLINICALMEDICINE, 2023, 66
1